601607 上海医药
已收盘 09-30 15:00:00
资讯
新帖
简况
9.48亿元买入、13.36亿元卖出！上海医药拟出售所持ZIL股权，标的去年营收超3.5亿澳元
每日经济新闻 · 09-30
9.48亿元买入、13.36亿元卖出！上海医药拟出售所持ZIL股权，标的去年营收超3.5亿澳元
上海医药：拟不低于1.99亿美元出售Zeus Investment Limited及其附属公司股权
格隆汇 · 09-29
上海医药：拟不低于1.99亿美元出售Zeus Investment Limited及其附属公司股权
上海医药（601607）披露紫杉醇注射液获得批准生产的公告，9月28日股价下跌0.81%
证券之星 · 09-28
上海医药（601607）披露紫杉醇注射液获得批准生产的公告，9月28日股价下跌0.81%
沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花
央广财经 · 09-28
沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花
上海医药最新公告：艾司奥美拉唑镁肠溶胶囊获批准生产
证券之星 · 09-28
上海医药最新公告：艾司奥美拉唑镁肠溶胶囊获批准生产
上海医药(601607.SH)：注射用硫酸艾沙康唑获得批准生产
智通财经 · 09-28
上海医药(601607.SH)：注射用硫酸艾沙康唑获得批准生产
上海医药：下属公司紫杉醇注射液获药品注册证书
财中社 · 09-28
上海医药：下属公司紫杉醇注射液获药品注册证书
每周股票复盘：上海医药（601607）盐酸林可霉素通过一致性评价
证券之星 · 09-13
每周股票复盘：上海医药（601607）盐酸林可霉素通过一致性评价
上海医药：每股派0.10元，股权登记日为9月17日
南方财经网 · 09-11
上海医药：每股派0.10元，股权登记日为9月17日
股市必读：上海医药新发布《上海医药集团股份有限公司2026年半年度权益分派实施公告》
证券之星 · 09-11
股市必读：上海医药新发布《上海医药集团股份有限公司2026年半年度权益分派实施公告》
上海医药(601607.SH)下属公司盐酸林可霉素注射液通过仿制药一致性评价
智通财经 · 09-10
上海医药(601607.SH)下属公司盐酸林可霉素注射液通过仿制药一致性评价
股市必读：上海医药（601607）9月9日董秘有最新回复
证券之星 · 09-10
股市必读：上海医药（601607）9月9日董秘有最新回复
上海医药：若涉及大股东减持事宜会及时履行信息披露义务
证券之星 · 09-09
上海医药：若涉及大股东减持事宜会及时履行信息披露义务
上海医药与上海药物所达成战略合作
第一财经 · 09-07
上海医药与上海药物所达成战略合作
上海医药：8月28日进行路演，东北证券、中信证券等多家机构参与
证券之星 · 09-07
上海医药：8月28日进行路演，东北证券、中信证券等多家机构参与
上海医药公布2026财年中期权益分配方案
同花顺 · 09-03
上海医药公布2026财年中期权益分配方案
上海医药：八宝丹传统制作技艺入选福建省级非遗代表性项目
证券之星 · 09-02
上海医药：八宝丹传统制作技艺入选福建省级非遗代表性项目
投资收益“断崖式”退潮，上海医药上半年净利润下滑超两成，应收账款逼近千亿元
深圳商报·读创 · 09-02
投资收益“断崖式”退潮，上海医药上半年净利润下滑超两成，应收账款逼近千亿元
股市必读：上海医药新发布《上海医药集团股份有限公司关于磷酸芦可替尼片获得批准生产的公告》
证券之星 · 09-02
股市必读：上海医药新发布《上海医药集团股份有限公司关于磷酸芦可替尼片获得批准生产的公告》
上海医药上半年营收超1400亿元 应收账款规模有所扩张
经济参考网 · 09-01
上海医药上半年营收超1400亿元 应收账款规模有所扩张
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是药品、医疗器械、大健康产品、医药商业。公司再度入选《财富》世界500强和《PharmExec》2026全球制药企业50强榜单，排名为第411位和第39位。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.22,"timestamp":1790751600000,"preClose":16,"halted":0,"volume":11424775,"delay":0,"changeRate":0.0137,"floatShares":2789000000,"shares":3708000000,"eps":1.2864,"marketStatus":"已收盘","change":0.22,"latestTime":"09-30 15:00:00","open":16,"high":16.28,"low":15.99,"amount":185000000,"amplitude":0.0181,"askPrice":16.22,"askSize":332,"bidPrice":16.21,"bidSize":122,"shortable":0,"etf":0,"ttmEps":1.2864,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":16,"symbolType":"stock","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":17.6,"lowLimit":14.4,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.77,"roa":"--","peRate":12.608831,"roe":"4.51%","epsLYR":1.54,"committee":-0.831899,"marketValue":60150000000,"turnoverRate":0.0041,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-08。","hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":10.84,"timestamp":1790928489008,"preClose":11.08,"halted":0,"volume":1026002,"delay":0,"premium":"-42.88"},"floatMarketCap":45241000000},"requestUrl":"/m/hq/s/601607/","defaultTab":"news","newsList":[{"id":"2671622323","title":"9.48亿元买入、13.36亿元卖出！上海医药拟出售所持ZIL股权，标的去年营收超3.5亿澳元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671622323","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671622323?lang=zh_cn&edition=full","pubTime":"2026-09-30 07:51","pubTimestamp":1790725887,"startTime":"0","endTime":"0","summary":"9月29日晚间，上海医药（SH601607，股价16元，市值593亿元）公告称，公司拟与春华资本共同出售ZeusInvestmentLimited（以下简称ZIL或标的公司）及其附属公司全部股权，标的公司企业价值确定为3.97亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609303887043645.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609303887043645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671094214","title":"上海医药：拟不低于1.99亿美元出售Zeus Investment Limited及其附属公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2671094214","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671094214?lang=zh_cn&edition=full","pubTime":"2026-09-29 20:49","pubTimestamp":1790686195,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0187","BK0196","BK0175","BK0188","BK0209","BK0183","BK0097","BK0012","BK0020","601607","BK0099","BK0184","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670253228","title":"上海医药（601607）披露紫杉醇注射液获得批准生产的公告，9月28日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670253228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670253228?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:14","pubTimestamp":1790604868,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，上海医药报收于15.89元，较前一交易日下跌0.81%，最新总市值为589.26亿元。该股当日开盘16.01元，最高16.11元，最低15.83元，成交额达1.41亿元，换手率为0.32%。近日，上海医药集团股份有限公司发布关于紫杉醇注射液获得批准生产的公告。公告显示，公司下属上海金和生物制药有限公司收到国家药品监督管理局颁发的《药品注册证书》，紫杉醇注射液获得批准生产。截至公告日，公司已投入研发费用约451万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800034726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK1197","BK0097","BK0175","BK0209","BK0099","BK0184","BK0183","BK0028","BK0196","02607","601607","BK0187","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670875258","title":"沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花","url":"https://stock-news.laohu8.com/highlight/detail?id=2670875258","media":"央广财经","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670875258?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:22","pubTimestamp":1790601766,"startTime":"0","endTime":"0","summary":"央广网北京9月28日消息（记者牛谷月）9月28日晚间，沪市（含科创板）超20家上市公司集中发布多项利好公告，内容涵盖股份回购增持、资产重组、药品获批、重大经营合同落地等。多家企业以真金白银彰显对自身长期发展的信心，同时披露业务拓展新进展，向市场传递积极信号。回购增持成为本次晚间公告的重头戏，共有12家公司发布相关方案或实施进展。其中，两家公司抛出全新回购预案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885425388.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885425388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600690","BK0277","603195","BK0209","BK0201","BK0097","IE0005HP3H50.USD","LU1794554557.SGD","LU0456827905.SGD","SGXZ81163826.USD","BK0020","BK0235","BK0188","LU1580142542.USD","LU2097828474.EUR","603310","BK0000","BK0231","BK0067","603707","BK0010","BK0026","BK0196","605303","688349","LU1720050803.USD","BK0183","BK0028","BK0012","BK0259","LU1969619763.USD","BK0175","LU2148510915.USD","601126","688032","601607","601117","LU2097828805.USD","688111","BK0187","LU0456846285.SGD","688251","BK0184","SGXZ49509284.SGD","BK0044","LU2580892862.HKD","600720","BK0015","603296","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670233026","title":"上海医药最新公告：艾司奥美拉唑镁肠溶胶囊获批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2670233026","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670233026?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:42","pubTimestamp":1790588538,"startTime":"0","endTime":"0","summary":"上海医药(601607.SH)公告称，公司下属常州制药厂收到国家药监局颁发的艾司奥美拉唑镁肠溶胶囊《药品注册证书》，该药品获得批准生产。该药品适用于胃食管反流病、根除幽门螺杆菌等，公司已投入研发费用约519万元。2025年中国大陆医院采购该药品金额为6.39亿元。此次获批有利于扩大市场份额，但存在销售不达预期风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800022872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK1197","BK0097","BK0175","BK0209","BK0099","BK0184","BK0183","BK0028","BK0196","02607","601607","BK0187","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670877212","title":"上海医药(601607.SH)：注射用硫酸艾沙康唑获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2670877212","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670877212?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:27","pubTimestamp":1790584048,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上药东英(江苏)药业有限公司(以下简称“上药东英”)收到国家药品监督管理局(以下简称“国家药监局”)颁发的关于注射用硫酸艾沙康唑(以下简称“该药品”)的《药品注册证书》(证书编号：2026S03379)，该药品获得批准生产。注射用硫酸艾沙康唑适用于治疗成人和1岁及以上儿童患者下列感染：侵袭性曲霉病、侵袭性毛霉病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0196","BK0209","BK0099","BK0184","BK0097","02607","BK0028","BK0020","BK0183","BK0012","BK1197","601607","BK0175","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670723287","title":"上海医药：下属公司紫杉醇注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2670723287","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670723287?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:17","pubTimestamp":1790583420,"startTime":"0","endTime":"0","summary":"9月28日，上海医药（601607/02607）发布公告，近日，公司下属上海金和生物制药有限公司收到国家药品监督管理局颁发的关于紫杉醇注射液的《药品注册证书》，该药品获得批准生产。紫杉醇注射液适用于进展期卵巢癌的一线、后继治疗及淋巴结阳性的乳腺癌患者在含阿霉素标准方案联合化疗后的辅助治疗等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885220435.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885220435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0187","BK0188","BK0209","BK0028","02607","BK0184","BK1197","BK0020","BK0012","BK0175","BK0097","BK0183","BK0196","601607","BK0099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507911","title":"每周股票复盘：上海医药（601607）盐酸林可霉素通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507911","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507911?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:13","pubTimestamp":1789236790,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，上海医药报收于16.29元，较上周的16.62元下跌1.99%。公司公告汇总上海医药集团股份有限公司发布2026年半年度权益分派实施公告，本次利润分配经2025年年度股东会审议通过。上海医药集团股份有限公司下属上海禾丰制药有限公司收到国家药品监督管理局颁发的《药品补充申请批准通知书》，盐酸林可霉素注射液通过仿制药质量和疗效一致性评价。2025年7月，上药禾丰提交一致性评价申请并获受理，截至公告日研发投入约197万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0184","BK0028","02607","BK0099","BK0187","BK0183","BK0188","BK0209","BK0097","BK0012","601607","BK1197","BK0020","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666823540","title":"上海医药：每股派0.10元，股权登记日为9月17日","url":"https://stock-news.laohu8.com/highlight/detail?id=2666823540","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666823540?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:52","pubTimestamp":1789116720,"startTime":"0","endTime":"0","summary":"南财智讯9月11日电，上海医药发布2026年半年度权益分派实施公告，每股派0.10元（含税），股权登记日为9月17日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609113872118437.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609113872118437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0183","BK0097","BK0188","BK0184","BK0196","BK0209","BK0175","BK1197","BK0187","02607","BK0028","BK0020","BK0099","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666974865","title":"股市必读：上海医药新发布《上海医药集团股份有限公司2026年半年度权益分派实施公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666974865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666974865?lang=zh_cn&edition=full","pubTime":"2026-09-11 01:10","pubTimestamp":1789060222,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药下属上海禾丰制药有限公司盐酸林可霉素注射液通过仿制药一致性评价，2025年该药品中国大陆医院采购金额为2168万元，截至公告日研发投入约197万元。公司公告汇总上海医药集团股份有限公司2026年半年度权益分派实施公告本次利润分配经2026年6月25日召开的2025年年度股东会审议通过，每股派发现金红利0.10元（含税），以公司总股本3,708,361,809股为基数，共计派发现金红利370,836,180.90元，其中A股现金红利278,928,910.50元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100002017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0099","601607","BK0028","BK0209","BK0175","BK0196","BK0184","BK0187","BK0183","BK0188","02607","BK0012","BK1197","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567287","title":"上海医药(601607.SH)下属公司盐酸林可霉素注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567287","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666567287?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:53","pubTimestamp":1789037606,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海禾丰制药有限公司收到国家药品监督管理局颁发的关于盐酸林可霉素注射液的《药品补充申请批准通知书》，该药品通过仿制药一致性评价。该药品适用于由链球菌、肺炎球菌和葡萄球菌等敏感菌株引起的严重感染，但仅适用于对青霉素过敏的患者或经医生判断不宜使用青霉素的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0012","02607","BK0184","BK0183","BK0188","BK1197","BK0196","BK0097","BK0187","BK0028","BK0099","601607","BK0020","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666532844","title":"股市必读：上海医药（601607）9月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2666532844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666532844?lang=zh_cn&edition=full","pubTime":"2026-09-10 01:32","pubTimestamp":1788975135,"startTime":"0","endTime":"0","summary":"截至2026年9月9日收盘，上海医药报收于16.48元，下跌0.54%，换手率0.2%，成交量5.63万手，成交额9282.21万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000002038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0097","BK0188","BK0175","BK1197","02607","BK0012","BK0028","BK0184","BK0099","BK0187","601607","BK0196","BK0020","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666581029","title":"上海医药：若涉及大股东减持事宜会及时履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2666581029","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666581029?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:57","pubTimestamp":1788947825,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药(601607)09月09日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，云南白药的36个月的减持期已经结束，该公司是否考虑减持公司股票？上海医药回复：尊敬的投资者您好，若涉及大股东减持事宜，公司会按照监管规则的要求及时履行相应的信息披露义务。目前题述一事暂未涉及，感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900030720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0028","BK0187","BK0196","BK1197","601607","BK0020","BK0209","BK0183","BK0188","BK0097","BK0099","BK0184","02607","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665312645","title":"上海医药与上海药物所达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2665312645","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665312645?lang=zh_cn&edition=full","pubTime":"2026-09-07 21:51","pubTimestamp":1788789109,"startTime":"0","endTime":"0","summary":"【上海医药与上海药物所达成战略合作】上海医药消息，9月7日，上海医药集团股份有限公司与中国科学院上海药物研究所签署合作框架协议。双方将围绕创新药物研发及成果转化开展深度合作，进一步推动科研端与产业端优势衔接，共同提升创新成果转化效率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866983664.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866983664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","BK0175","BK0099","BK0183","BK0028","BK0196","BK0209","BK0188","02607","BK0012","BK0097","BK0184","601607","BK0187","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665731171","title":"上海医药：8月28日进行路演，东北证券、中信证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2665731171","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665731171?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:44","pubTimestamp":1788774272,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月2日上海医药发布公告称公司于2026年8月28日进行路演，东北证券、中信证券、中金公司、中信建投、兴业证券、西南证券、中邮证券、仁桥资产、中欧基金参与。截至6月底，B007重症肌无力适应症II期临床试验已完成全部受试者出组和临床总结报告定稿。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1564","LU1794554557.SGD","BK0184","BK0276","BK0175","LU1328615791.USD","LU2580892862.HKD","BK0099","LU1580142542.USD","BK0183","BK0097","LU1820825898.SGD","LU1064130708.USD","LU1064131003.USD","02607","LU2495084118.USD","BK1147","LU2148510915.USD","BK0012","BK1516","06030","BK0196","BK0209","LU1997245177.USD","LU0405327148.USD","LU1997245094.SGD","LU0405327494.USD","LU1720050803.USD","LU2289578879.USD","BK0028","000686","BK0020","BK0188","601607","LU1146622755.USD","LU1997244956.HKD","LU1655091616.SGD","600030","BK1197","LU2580892789.USD","BK1521","BK0187","LU1255011170.USD","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664876257","title":"上海医药公布2026财年中期权益分配方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2664876257","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664876257?lang=zh_cn&edition=full","pubTime":"2026-09-03 18:50","pubTimestamp":1788432600,"startTime":"0","endTime":"0","summary":"上海医药（HK02607）9月3日发布公告，公司将于2026年10月23日一般分红每股0.11663港元 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260903/c679574366.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260903/c679574366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0187","BK0196","BK0175","BK0188","BK0209","BK0183","BK0097","BK0012","BK0020","601607","BK0099","BK0184","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664989086","title":"上海医药：八宝丹传统制作技艺入选福建省级非遗代表性项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2664989086","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664989086?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:12","pubTimestamp":1788340334,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药09月02日在投资者关系平台上答复投资者关心的问题。拥有“鼎炉”中华老字号、多项省市级非物质文化遗产、中国驰名商标等资质。上药厦中所传承的八宝丹传统制作技艺，于今年入选福建省级非遗代表性项目。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200030257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0028","BK0012","BK0184","BK0209","BK1197","BK0175","BK0097","BK0099","601607","02607","BK0020","BK0188","BK0196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664980368","title":"投资收益“断崖式”退潮，上海医药上半年净利润下滑超两成，应收账款逼近千亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664980368","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664980368?lang=zh_cn&edition=full","pubTime":"2026-09-02 10:52","pubTimestamp":1788317531,"startTime":"0","endTime":"0","summary":"深圳商报·读创客户端记者张弛近日，上海医药集团股份有限公司（601607.SH/02607.HK）披露的2026年半年度报告显示，公司上半年实现营业收入1474.70亿元，同比增长4.15%；实现归属于上市公司股东的净利润35.04亿元，同比下降21.40%；基本每股收益0.95元，同比下降20.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862592729.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862592729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664686315","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于磷酸芦可替尼片获得批准生产的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664686315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664686315?lang=zh_cn&edition=full","pubTime":"2026-09-02 01:40","pubTimestamp":1788284423,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药下属常州制药厂有限公司磷酸芦可替尼片获国家药监局批准生产，系国内第二家获批企业，此前仅诺华在境内供应；2025年该药国内医院采购额达7.168亿元。公司公告汇总上海医药集团股份有限公司关于磷酸芦可替尼片获得批准生产的公告上海医药集团股份有限公司下属常州制药厂有限公司收到国家药品监督管理局颁发的《药品注册证书》，磷酸芦可替尼片获得批准生产。中国境内此前仅有瑞士诺华制药生产该药品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200001987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0183","BK0097","BK0188","BK0184","BK0196","BK0209","BK0175","BK1197","BK0187","02607","BK0028","BK0020","BK0099","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664546854","title":"上海医药上半年营收超1400亿元 应收账款规模有所扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=2664546854","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664546854?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:26","pubTimestamp":1788269162,"startTime":"0","endTime":"0","summary":"近日，上海医药（601607.SH）披露2026年半年报。在医药流通行业整体仍处于调整期的背景下，公司扣非归母净利润实现两位数增长，主业盈利韧性凸显，公司应收账款规模随业务拓展有所扩张，资产质量与运营效率的平衡成为新课题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013861720732.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013861720732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["601607","02607"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791153702884,"stockEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0043},{"period":"3month","weight":0.0467},{"period":"6month","weight":-0.0373},{"period":"1year","weight":-0.0653},{"period":"ytd","weight":-0.0606}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"0人","perCapita":"--","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是药品、医疗器械、大健康产品、医药商业。公司再度入选《财富》世界500强和《PharmExec》2026全球制药企业50强榜单，排名为第411位和第39位。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}